Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.
Microdose GLP OneMicrodosing evidence & price desk · Updated September 4, 2026

The GLP-1 ledger: what changed by August 2026

Published August 10, 2026 · Microdose GLP One editorial team · figures verified against publishers’ own pages

Five developments define the market this month — three about price, two about supply — and each one moves a number this site tracks. Dated, sourced, and in plain sentences.

1. Wegovy HD launched at $399. The 7.2 mg semaglutide dose approved March 19 (54-day accelerated review, ~20.7% average weight loss in STEP UP) reached pharmacies in April and prices at $399 a month cash through NovoCare — a $50 step over the standard $349 pens, with the $199 two-fill intro for new patients still running through year-end. The full analysis is in our HD breakdown.

2. Brand subscriptions arrived: $249 a month on a 12-month commitment. Since March 31, Ro, WeightWatchers, and LifeMD sell the first multi-month brand Wegovy plans — pens at $329/$299/$249 on 3/6/12-month terms. That is brand-name semaglutide $84 a month above the cheapest verified compounded flat rate, the narrowest that gap has ever been.

3. The pill's entry price expires August 31. The oral Wegovy 4 mg dose has been $149 a month as a limited offer; after August 31 it steps to $199 (the 1.5 mg stays at $149). Anyone anchoring on "$149 pill" should re-check the fine print in three weeks.

4. A second oral arrived: orforglipron. April also brought approval of the first oral small-molecule GLP-1 — no food or water timing restrictions, easier to manufacture at scale, with roughly 12% average weight loss at the top dose. Less potent than the injectables, but a genuine access story, and price pressure on everything below it.

5. The 503B door is closing. The FDA's April 30 proposal would permanently exclude semaglutide, tirzepatide, and liraglutide from the bulk-compounding list — foreclosing mass compounding even in a future shortage — with the extended comment window closing in early August and no final determination yet. The agency cited 455+ adverse-event reports tied to compounded semaglutide and 320+ for tirzepatide, many from self-dosing errors, alongside 2026 findings that tirzepatide chemically bonds with the vitamin B12 many compounders add. Patient-specific 503A prescribing continues; the era of at-scale compounded GLP-1s is ending on paper before our eyes. What that means for microdose programs: named pharmacies, base-molecule formulations, and month-to-month billing are the only sane defaults this year — the case our compounding explainer has made since launch.

Every figure above was verified August 9–10, 2026 against the publishers' own pages; the running file lives in the news desk, updated as items land.

Questions people ask

What's the biggest GLP-1 price change in August 2026?

The oral Wegovy 4 mg offer ends August 31 — $149 steps to $199. The $249/month 12-month brand subscription (Ro/WeightWatchers/LifeMD) remains the cheapest way to buy brand semaglutide.

Is compounded GLP-1 going away?

Bulk compounding likely is: the FDA proposed permanently excluding semaglutide and tirzepatide from the 503B list, with the comment period closing in early August 2026. Patient-specific 503A prescriptions remain legal.

Sources & references

Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.